Galvin Gaustad & Stein LLC Raises Stake in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Galvin Gaustad & Stein LLC increased its holdings in United Therapeutics by 15.0%, now owning 30,488 shares valued at approximately $9.4 million.
• Recent insider trading saw EVP Paul A. Mahon and CFO James Edgemond sell significant portions of their shares, with Mahon selling 11,000 shares and Edgemond selling 12,000 shares.
• Several analysts have revised their price targets for United Therapeutics, with Morgan Stanley lowering their target from $348 to $328 while maintaining an "equal weight" rating.

Galvin Gaustad & Stein LLC increased its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 15.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,488 shares of the biotechnology company's stock after buying an additional 3,976 shares during the quarter. Galvin Gaustad & Stein LLC owned about 0.07% of United Therapeutics worth $9,399,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Dunhill Financial LLC raised its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares in the last quarter. Sound Income Strategies LLC purchased a new position in shares of United Therapeutics in the first quarter worth approximately $49,000. State of Wyoming purchased a new position in shares of United Therapeutics in the fourth quarter worth approximately $62,000. Curat Global LLC purchased a new position in shares of United Therapeutics in the first quarter worth approximately $63,000. Finally, Natixis purchased a new position in shares of United Therapeutics in the fourth quarter worth approximately $85,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Trading Down 0.2%

NASDAQ:UTHR traded down $0.58 on Tuesday, reaching $297.56. 527,065 shares of the stock traded hands, compared to its average volume of 491,403. The company's fifty day simple moving average is $299.87 and its 200 day simple moving average is $315.03. The company has a market capitalization of $13.42 billion, a price-to-earnings ratio of 11.87, a PEG ratio of 6.64 and a beta of 0.53. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.17 earnings per share. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Morgan Stanley decreased their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price for the company. Finally, Bank of America cut their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $383.08.

Insider Buying and Selling at United Therapeutics

In related news, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. The trade was a 11.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at $11,185,469.91. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,681 shares of company stock worth $24,628,589. Company insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.